Analysis
Iambic Therapeutics priced its IPO at $16.00 a share, the midpoint of its $15-to-$17 range, selling 9,375,000 shares for $150 million in gross proceeds, and began trading Thursday on the Nasdaq Global Select Market under the ticker IAM, with shares rising roughly 13% to 16% in afternoon trading, according to BusinessWire. Pulse covered Iambic's initial $150M IPO terms when the range was first set, then its upsized demand signal last week — what's new Thursday is that the deal actually priced and started trading, rather than just setting terms: it held the middle of its range and still popped 13-16% on debut, confirming the demand both earlier stories only inferred.
J.P. Morgan, Jefferies, BofA Securities and Citigroup served as joint bookrunners. ARK Investment Management and Duquesne Family Office had indicated interest in roughly $60 million of shares ahead of pricing, giving underwriters confidence to hold the midpoint rather than discount into a soft market, a problem that hit several other 2026 biotech offerings. Nvidia and Qatar Investment Authority are both strategic backers, underscoring how AI-drug-discovery startups are increasingly raising from tech-strategic money alongside traditional biotech crossover funds.
“Morgan, Jefferies, BofA Securities and Citigroup served as joint bookrunners.”
Iambic's AI platform designs small-molecule drugs computationally before lab validation; its lead candidate, IAM1363, targets HER2 and remains in Phase 1/1b trials, meaning this IPO prices almost entirely on the platform's promise rather than any near-term clinical readout. The debut pop is the more useful data point for the broader biotech-IPO market than for Iambic alone: it's a real, tradeable comp the next AI-drug-discovery company filing an S-1 can point to, at a moment when 2026's biotech IPO window has stayed open longer than many expected.